azacitidine has been researched along with imatinib mesylate in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 11 (55.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Giles, FJ; Jabbour, EJ | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jelinek, J; Kantarjian, HM; Morris, G; Talpaz, M; Verstovsek, S | 1 |
| Odenike, O; Tefferi, A | 1 |
| Cortes, J; Kantarjian, HM | 1 |
| Pu, Q | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jones, D; Kantarjian, HM; Morris, GM; O'brien, S; Oki, Y; Verstovsek, S | 1 |
| Agirre, X; Arqueros, V; Cervantes, F; Cordeu, L; Fresquet, V; Gárate, L; Heiniger, A; Jiménez-Velasco, A; Martín, V; Martínez-Climent, JA; Prósper, F; Roman-Gomez, J; San José-Eneriz, E; Torres, A | 1 |
| Akbulak, R; Atanackovic, D; Bartels, BM; Bartels, K; Bokemeyer, C; Brümmendorf, TH; Cao, Y; Gontarewicz, A; Gordic, M; Hildebrandt, Y; Kobold, S; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Schafhausen, P; Stasche, T; Uhlich, F | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Cullus, P; Erneux, C; Gromova, P; Rubin, BP; Thys, A; Vanderwinden, JM | 1 |
| Chan, KW; Lockhart, S; McDonald, L; Rytting, M | 1 |
| Liang, G; Liang, JF; Wu, LN; Xiao, H; Zhao, YZ; Zheng, HX | 1 |
| Wu, J | 1 |
| Ishikawa, T | 1 |
| Abdelhay, E; Binato, R; Cappelletti, P; Corrêa, S; Du Rocher, B; Ferreira, G; Mencalha, A; Pinto, LF; Soares-Lima, S | 1 |
| Amarante-Mendes, GP; Calle, Y; Castro, FA; De Carvalho, DD; Hamerschlak, N; Jacysyn, JF; Jones, GE; Pagnano, KB; Pereira, WO; Ribeiro, BF; Sardinha, LR; Zanichelli, MA; Zenteno, ME | 1 |
| Al-Jamal, HAN; Ismail, I; Johan, MF; Mat Jusoh, SA; Wan Taib, WR | 1 |
5 review(s) available for azacitidine and imatinib mesylate
| Article | Year |
|---|---|
New agents in myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2005 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
New strategies in chronic myeloid leukemia.
Topics: Angiogenesis Inhibitors; Azacitidine; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Decitabine; Drug Resistance, Neoplasm; Farnesyl-Diphosphate Farnesyltransferase; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2006 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
2 trial(s) available for azacitidine and imatinib mesylate
| Article | Year |
|---|---|
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Blast Crisis; Decitabine; DNA Methylation; Female; Genes, abl; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
13 other study(ies) available for azacitidine and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Decitabine has promising clinical activity in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Failure | 2002 |
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
[Further improving the standard of treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2006 |
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2009 |
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunity, Humoral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines | 2010 |
ENDOGLIN/CD105 is expressed in KIT positive cells in the gut and in gastrointestinal stromal tumours.
Topics: Animals; Antigens, CD; Antigens, CD34; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Endoglin; Endothelium, Vascular; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interstitial Cells of Cajal; Mice; Mice, Transgenic; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Cell Surface; RNA, Messenger; Signal Transduction | 2012 |
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2012 |
[Therapeutic effect of in vitro 5-aza-2'-deoxycytidine combined with imatinib on gastrointestinal stromal tumor].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Decitabine; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines | 2012 |
New views and new tools for complex diseases.
Topics: Animals; Azacitidine; Benzamides; Disease; Ficolins; Gene Regulatory Networks; Humans; Imatinib Mesylate; Lectins; Mice; Piperazines; Pyrimidines; Regenerative Medicine; Tumor Suppressor Protein p53 | 2012 |
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Promoter Regions, Genetic; Pyrimidines | 2014 |
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinogenesis; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Promoter Regions, Genetic; Protein Kinase Inhibitors; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Wiskott-Aldrich Syndrome Protein | 2017 |
Re-Expression of Bone Marrow Proteoglycan-2 by 5-Azacytidine is associated with STAT3 Inactivation and Sensitivity\
Response to Imatinib in Resistant CML Cells
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Bone Marrow; Cell Proliferation; Drug Resistance, Neoplasm; Eosinophil Major Basic Protein; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proteoglycans; STAT3 Transcription Factor; Tumor Cells, Cultured | 2018 |